

Pressinformation 25 August, 2011

## Sweden based Prostalund to increase investments in the US BPH market

**Prostalund has developed a leading technology that offers minimal invasive treatment for Benign Prostatic Hyperplasia (BPH). CoreTherm® provides a unique and simple solution for relief of enlarged prostate and is a proven alternative to surgery and symptom-controlling medication.**

**To further enhance its position in the US market, the company has decided to establish a 100% owned US subsidiary under the name CoreTherm Medical, Inc. effective from September 1st 2011. The company is located in Oldsmar, Florida.**

*"This is an important step forward in our ambition to become a significant player also in the US BPH market. With rapid demographical changes, we see a long term opportunity by offering a highly effective treatment modality without the need of allocating time in the operating room, post-operative wards and other resource consuming structures in the healthcare sector" says Mr. Ulf Rosén, President & CEO Prostalund group.*

*He continues "Establishing a US subsidiary is also a clear signal to the market that we continue our strong commitment to patients suffering from BPH."*

Benign prostatic hyperplasia can cause a great deal of discomfort and frustration resulting from the inability to urinate normally. BPH occurs in approximately half of all men aged 50 years and older and up to 80% of men at 80 years of age. Benign prostatic hyperplasia (BPH) is not cancer. However, left untreated BPH may damage your bladder and kidneys and drastically impact your quality of life. CoreTherm utilizes a unique patented method to measure the actual core temperature in the prostate during treatment. The temperature in the prostate tissue is measured with a specially designed intraprostatic temperature probe and monitored throughout the treatment. The overall aim of the therapy is to create an opening for the urine to pass through thereby reducing the symptoms and increasing urinary flow.

CoreTherm significantly reduces BPH symptoms, preserves sexual function, and provides durable results. Treatment can be completed within 10 to 30 minutes, does not require general anesthesia, and is performed in the comfort of a physician's office or an outpatient setting.

For more information, please contact

Anders Elf, President  
CoreTherm Medical, Inc.  
727 216 8080  
anders.elf@coretherm.com

Ulf Rosén, President & CEO  
Prostalund Group  
+46 706 86 29 16  
ulf.rosen@prostalund.com